(A) sfGFP intensities and mCherry/sfGFP ratios (n = 4), normalized to the median of each screen, for tFT-Pex15Δ30 and tFT-Tom5 expressed in an array of mutants in the ubiquitin-proteasome system. (B) Normalized mCherry/sfGFP ratios for the indicated mutants in each screen. DUB, deubiquitinating enzymes, E2, ubiquitin-conjugating enzymes, E3, ubiquitin ligases. Red dashed lines mark the median of each screen. (C) Cycloheximide chase analysis and quantification (n = 3, ± SEM) of tFT-Pex15Δ30 (FL) expressed in wt, msp1Δ, doa10Δ, and msp1Δdoa10Δ, and hrd1Δ strains. WB, western blot. Pgk1 serves as loading control. (D) Growth curves of indicated yeast strains expressing tFT-Pex15Δ30 during 20 hr of growth (n = 3, ± SEM). (E) Cycloheximide chase of pdr5Δ yeast strains expressing sfGFPcp8-Pex15Δ30 pre-treated with the proteasome inhibitors MG132 (80 μM) and bortezomib (100 μM). Gray arrow, uncharacterized sfGFP degradation intermediate. (F) Cycloheximide chase of plasmid expressed Ste6*-HA in wt, get3Δ and doa10Δ strains with quantification (n = 3, ± SEM).